Thoratec Corp. CEO Gerhard F. Burbach Sells 9,400 Shares (THOR)
Thoratec Corp. (NASDAQ:THOR) CEO Gerhard F. Burbach unloaded 9,400 shares of Thoratec Corp. stock on the open market in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $38.10, for a total transaction of $358,140.00. Following the transaction, the chief executive officer now directly owns 156,307 shares in the company, valued at approximately $5,955,297. The sale was disclosed in a document filed with the SEC, which is available at this link.
Thoratec Corp. (NASDAQ:THOR) traded down 1.71% on Friday, hitting $37.32. 441,545 shares of the company’s stock traded hands. Thoratec Corp. has a 52 week low of $29.91 and a 52 week high of $43.58. The stock’s 50-day moving average is $37.07 and its 200-day moving average is $37.11. The company has a market cap of $2.126 billion and a price-to-earnings ratio of 48.49.
Thoratec Corp. (NASDAQ:THOR) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.49 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.40 by $0.09. The company had revenue of $126.40 million for the quarter, compared to the consensus estimate of $121.25 million. During the same quarter in the prior year, the company posted $0.41 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts expect that Thoratec Corp. will post $1.83 EPS for the current fiscal year.
A number of analysts have recently weighed in on THOR shares. Analysts at Zacks reiterated a “neutral” rating on shares of Thoratec Corp. in a research note to investors on Monday, January 6th. They now have a $38.00 price target on the stock. Separately, analysts at Northland Securities raised their price target on shares of Thoratec Corp. from $42.00 to $46.00 in a research note to investors on Thursday, October 31st. Finally, analysts at Barclays raised their price target on shares of Thoratec Corp. from $43.00 to $45.00 in a research note to investors on Thursday, October 31st. They now have an “overweight” rating on the stock. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $44.90.
Thoratec Corporation is engaged in mechanical circulatory support with a product portfolio to treat the range of clinical needs for advanced heart failure (NASDAQ:THOR) patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.